STAAR Surgical (STAA) Stock Forecast & Price Target

Staar Surgical is benefiting from a durable China recovery, with 2Q’26 net sales of $93.5M up 111.0% year over year and China revenue of $52.3M rising over 100%, while EVO+ adoption reached roughly a third of China ICL units and distributor inventory remains aligned with end demand. The company’s profitability inflection is also strengthening, as adj. EBITDA surged to $20.0M with a 21.4% margin, gross margin improved to 74.5%, and cash and investments increased to $181.5M with the company remaining debt-free. Permanent CEO Warren Foust’s appointment, along with evidence that the Alcon-related disruption was mechanical rather than structural, supports operating discipline and long-term value creation, while strong brand equity, proprietary ICL technology, and ex-China growth provide multiple avenues for continued expansion.

Staar Surgical is facing a more cautious fundamental outlook because expected revenue for FY’26 has been revised slightly lower, which weakens the growth profile supporting the shares. The company remains heavily dependent on its ICL franchise, so any softness in implantable lens demand or slower execution in key international markets can have an outsized effect on results. Although long-term prospects and a re-acceleration of growth in China are still viewed positively, the need to re-weight probability scenarios signals greater uncertainty around near-term revenue momentum and valuation support.